Comparison of two non-invasive models for advanced fibrosis detection in T2D and MASLD using LiverSTAT, FIB-4 and LSM (Saudi Arabia) easlfibronostg on June 29, 2026 Category: Publications Tag: Diabetes, Identification, LiverSTAT, MASLD Post navigation Previous: Previous post: Evaluation of LIVERFASt for staging fibrosis in MASLD patients in NIDDK studies using liver biopsyNext: Next post: LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patients
